Incannex (ASX:IHL) and Monash uni to combine virtual reality and psychedelics for anxiety treatment – ​​The Market Herald

Subscribe

Be the first with the news that moves the market

  • Incannex Healthcare (IHL) executes a license agreement with Monash University to develop an anxiety treatment combining virtual reality (VR) and psychedelics
  • The new treatment is for severe anxiety disorders and uses an exposure-based approach to provide triggering stimuli in a graded and controlled manner
  • Three license fees are outlined in the agreement and payable upon the decision by Incannex to proceed to subsequent phases of the research program
  • Incannex and Monash are working towards a research agreement for the first trials which will assess the optimal dose, safety, and tolerability of the combination treatment method
  • Shares in IHL are trading down, falling 3.42 per cent to 70.5 cents

Incannex Healthcare (IHL) has executed a license agreement with Monash University to develop an anxiety treatment combining virtual reality (VR) and psychedelics.

This marks the second clinical psychedelic therapy program for the clinical-stage pharmaceutical company developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs.

The new treatment is for severe anxiety disorders and uses an exposure-based approach to provide triggering stimuli in a graded and controlled manner.

With specialized clinical support and a psychedelic drug, Incannex said the approach may allow for the development of new skills, changes in mental and biological responses to triggering stimuli, and reductions in pathological symptoms and behaviours.

The research and development project will be funded by Incannex and undertaken by Monash, led by Dr Paul Liknaitzky.

Three license fees are payable to Monash under the agreement, including $300 thousand upon execution of the license agreement, $250 thousand should Incannex choose to proceed to a second trial, and another $250 thousand for a third trial.

The grant of the license is also conditional on Incannex paying a royalty of 7.5 per cent of net sales, subject to successful commercialisation of a therapy.

Incannex and Monash are working towards a research agreement for the first trials which will assess the optimal dose, safety, and tolerability of the combination treatment method.

Incannex Chief Executive Officer and Managing Director Joel Latham said the combination of psychedelic compounds with evidence-based VR therapy is leading-edge in the field of mental health treatments.

“We look forward to providing more detail about the project in due course when clinical trial planning has been finalised,” said Mr Latham.

Shares in IHL were down 3.42 per cent to 70.5 cents at 12:05 pm AEDT.

Leave a Comment